Superiority of YM598 over atrasentan as a selective endothelin ETA receptor antagonist.

@article{Yuyama2004SuperiorityOY,
  title={Superiority of YM598 over atrasentan as a selective endothelin ETA receptor antagonist.},
  author={Hironori Yuyama and Yukiko Noguchi and Akira Fujimori and Masashi Ukai and Noriko Fujiyasu and Akiyoshi Ohtake and Shuichi Sato and Katsumi Sudoh and Masao Sasamata and K. Miyata},
  journal={European journal of pharmacology},
  year={2004},
  volume={498 1-3},
  pages={171-7}
}
The binding affinities of (E)-N-[6-methoxy-5-(2-methoxyphenoxy)[2,2'-bipyrimidin]-4-yl]-2-phenylethenesulfonamide monopotassium salt (YM598) for native human endothelin ETA and ETB receptors expressed in human coronary artery smooth muscle cells (CASMC) and a human melanoma cell line, SK-Mel-28, respectively, were examined, and the results compared with those for the endothelin receptor antagonists atrasentan and bosentan. The in vivo endothelin ETA receptor inhibitory activities of YM598 and… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-2 of 2 extracted citations

Endothelin receptor B protects granulocyte macrophage colony-stimulating factor mRNA from degradation.

The Journal of pharmacology and experimental therapeutics • 2015
View 2 Excerpts
Highly Influenced

Bosentan: a review of its use in the management of mildly symptomatic pulmonary arterial hypertension.

American journal of cardiovascular drugs : drugs, devices, and other interventions • 2009
View 1 Excerpt

Similar Papers

Loading similar papers…